Krystal Biotech, Inc.
Financials
Valuation Metrics
Krystal Biotech, Inc.'s Market Cap is $8.73B. At end of 2025 it was $7.14B. Ranked #943 of 3,116 in US market (top 30%), #302 of 1,472 on NASDAQ (top 21%), #45 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.73B | US#943/3,116 Sec#45/265 |
| Revenue | $440M | US#2,295/3,116 Sec#83/265 |
| Net Income | $241M | US#1,192/3,116 Sec#39/265 |
| Total Assets | $1.50B | US#2,254/3,116 Sec#68/265 |
| Net Assets | $1.36B | US#1,536/3,116 Sec#46/265 |
| Employees | 295 | US#2,411/3,116 Sec#111/265 |
| Value | ||
| P/E | 36.16x | US#1,775/3,116 Sec#47/265 |
| P/B | 6.42x | US#2,438/3,116 Sec#171/265 |
| PEG | 0.56x | US#668/3,116 Sec#22/265 |
| P/S | 19.82x | US#2,853/3,116 Sec#146/265 |
| EV/EBITDA | 38.05x | US#2,321/3,116 Sec#70/265 |
| FCF Yield | 2.95% | US#1,881/3,116 Sec#61/265 |
| Profitability | ||
| ROE | 17.77% | US#716/3,116 Sec#37/265 |
| ROA | 16.09% | US#198/3,116 Sec#24/265 |
| Op. Margin | 44.93% | US#182/3,116 Sec#11/265 |
| Revenue Growth | 22.63% | US#604/3,116 Sec#71/265 |
| Earnings Growth | 64.57% | US#395/3,116 Sec#19/265 |
| Financial Health | ||
| Debt Ratio | 10.41% | US#113/3,116 Sec#51/265 |
| Total Debt | $9M | US#2,835/3,116 Sec#201/265 |
| FCF | $258M | US#1,249/3,116 Sec#42/265 |
| Cash | $428M | US#1,167/3,116 Sec#64/265 |
| Current Ratio | 8.32x | US#304/3,116 Sec#93/265 |
| Net Debt/EBITDA | -1.92x | US#179/3,116 Sec#15/265 |
| Performance | ||
| 1Y Return | 49.96% | US#270/3,116 Sec#51/265 |
| 1M Return | -8.10% | US#2,164/3,116 Sec#149/265 |
| From 52W High | -22.58% | US#1,247/3,116 Sec#67/265 |
| 1Y MDD | -21.68% | US#466/3,116 Sec#14/265 |
| Trading | ||
| Volume | 1,138,771 shares | US#2,817/3,116 Sec#256/265 |
| Trading Value | $339M | US#1,417/3,116 Sec#105/265 |
| Per Share | ||
| EPS | $8.19 | US#386/3,116 Sec#10/265 |
| BPS | $46.10 | US#494/3,116 Sec#10/265 |
Company Info
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.